NovelMed Advances NM5072 for Multiple Ocular Disorders
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />Key Highlights <ul type="disc"><li style="margin-top:5pt; margin-bottom:5pt;">Multi-indication precedent: Biogen’s approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan.
Read the full story at News Ticker - markets.businessinsider.com →